Tyrosine Kinase Inhibitor Activity in Patients with NSCLC Harboring Uncommon EGFR Mutations: A Retrospective International Cohort Study (UpSwinG).
Sanjay PopatTe-Chun HsiaJen-Yu HungHyun Ae JungJin-Yuan ShihCheol Kyu ParkSeung Hyeun LeeTatsuro OkamotoHee Kyung AhnYong Chul LeeYuki SatoSung Sook LeeCeline MascauxHasan DaoudAngela MärtenSatoru MiuraPublished in: The oncologist (2022)
In a real-world setting, EGFR TKIs were the preferred treatment option in patients with uncommon EGFR mutations; strongest outcomes were seen in patients with major uncommon and compound mutations.